Year: 2024
Type: review
Abstract: Breast ultrasound is used in a wide variety of clinical scenarios, including both diagnostic and screening applications. Limitations of ultrasound, however, include its low specificity and, for automated breast ultrasound screening, the time necessary to review whole-breast ultrasound images. As of this writing, four AI tools that are approved or cleared by the FDA address these limitations. Current tools, which are intended to provide decision support for lesion classification and/or detection, have been shown to increase specificity among nonspecialists and to decrease interpretation times. Potential future applications include triage of patients with palpable masses in low-resource settings, preoperative prediction of axillary lymph node metastasis, and preoperative prediction of neoadjuvant chemotherapy response. Challenges in the development and clinical deployment of AI for ultrasound include the limited availability of curated training datasets compared with mammography, the high variability in ultrasound image acquisition due to equipment- and operator-related factors (which may limit algorithm generalizability), and the lack of postimplementation evaluation studies. Furthermore, current AI tools for lesion classification were developed based on 2D data, but diagnostic accuracy could potentially be improved if multimodal ultrasound data were used, such as color Doppler, elastography, cine clips, and 3D imaging.
DOI: 10.2214/ajr.23.30645
Language: English
Topic: AI in cancer detection
Subfield: Artificial Intelligence
Field: Computer Science
Domain: Physical Sciences
Keywords: artificial intelligence, breast ultrasound, lesion classification, lesion detection, decision support, neoadjuvant chemotherapy response, limited training data, algorithm generalizability, multimodal ultrasound, color Doppler ultrasound, elastography, 3D ultrasound, resource-limited settings
Open Access status: hybrid
OpenAlex ID: W4391813402
